Efficacy of the Peritoneovenous Shunt as Palliative Care for Patients with Advanced Cancer with Refractory Ascites: A Randomized Controlled Trial (JIVROSG-0803 Study).
6 affiliations
- 1Department of Diagnostic Radiology, National Cancer Center Hospital, Japan.
- 2Department of Radiology, Fukuchiyama City Hospital, Japan.
- 3Division of Interventional Radiology, Shizuoka Cancer Center, Japan.
- 4Department of Radiology and IVR Center, Nara Medical University, Japan.
- 5Department of Gastroenterology, Ryugasaki Saiseikai Hospital, Japan.
- 6Department of Gastroenterology, Niigata Prefectural Central Hospital, Japan.
Abstract
Purpose
A randomized controlled trial (UMIN-CTR 000003469) was conducted to evaluate the superiority of peritoneovenous shunt over other treatments for refractory ascites in patients with advanced cancer.Methods
The study included patients with advanced cancer with symptoms due to refractory ascites. They were randomly allocated in a 1:1 ratio to receive either peritoneovenous shunt placement (test group) or another treatment (control group). The area under the curve of the symptom improvement score was compared between the groups as the primary endpoint. The areas under the curve of the EuroQol 5-Dimension and 8-Item Short Form Health Survey were also compared between the groups, and adverse events were evaluated up to 4 weeks after enrollment or until the protocol treatment was discontinued.Results
Forty patients (test group, 20; control group, 20) were enrolled between November 2009 and July 2018. The mean areas under the curve of the symptom improvement score curves were 133.2 (95% confidence interval: 98.6-167.7) and 69.9 (95% confidence interval: 34.4-105.4) in the test and control groups, respectively. The mean area under the curve was significantly larger in the test group than in the control group, and the primary endpoint was met. No significant differences were observed between the groups in the 8-Item Short Form Health Survey and EuroQol 5-Dimension scores or the frequency of adverse events.Conclusions
Peritoneovenous shunt hunt significantly improved the symptoms due to refractory ascites compared with other treatments. Although it was not significantly more effective for improving the comprehensive quality of life evaluated with the 8-Item Short Form Health Survey and EuroQol 5-Dimension, peritoneovenous shunt may be considered the standard of care for patients with advanced cancer and refractory ascites.
Related
- Efficacy of Kinesio tape for central facial paralysis : A prospective, randomized sham-controlled, single-blinded clinical trial
- Comparison of analgesic efficacy and safety between liposomal bupivacaine and ropivacaine for paravertebral block in patients undergoing thoracoscopic lung tumor surgery: a prospective double-blind randomized controlled trial
- Efficacy of a weighted-vest aerobic dance intervention for enhancing lower extremity strength and mobility in older adults: a randomized controlled trial
- Efficacy and safety of Anas barbariae 200K in influenza-like illness: a randomized double-blind, placebo-controlled, multicenter study
- Efficacy and safety of antibody-drug conjugates in pretreated HER2-positive advanced breast cancer: a network meta-analysis of randomized controlled trials
BibTeX
@article{arai2026efficacy,
title = {{Efficacy of the Peritoneovenous Shunt as Palliative Care for Patients with Advanced Cancer with Refractory Ascites: A Randomized Controlled Trial (JIVROSG-0803 Study).}},
author = {Yasuaki Arai and Miyuki Sone and Yoshito Takeuchi and Shunsuke Sugawara and Takeshi Aramaki and Toshihiro Tanaka and Mikio Sato and Shinichi Morita},
journal = {Interventional radiology (Higashimatsuyama-shi (Japan)},
year = {2026},
month = oct,
doi = {10.22575/interventionalradiology.2025-0091},
url = {https://europepmc.org/article/MED/42909221},
note = {CC BY-NC},
}
RIS
TY - JOUR
TI - Efficacy of the Peritoneovenous Shunt as Palliative Care for Patients with Advanced Cancer with Refractory Ascites: A Randomized Controlled Trial (JIVROSG-0803 Study).
AU - Yasuaki Arai
AU - Miyuki Sone
AU - Yoshito Takeuchi
AU - Shunsuke Sugawara
AU - Takeshi Aramaki
AU - Toshihiro Tanaka
AU - Mikio Sato
AU - Shinichi Morita
PY - 2026
DA - 2026/10/05
JO - Interventional radiology (Higashimatsuyama-shi (Japan)
DO - 10.22575/interventionalradiology.2025-0091
UR - https://europepmc.org/article/MED/42909221
AB - Purpose A randomized controlled trial (UMIN-CTR 000003469) was conducted to evaluate the superiority of peritoneovenous shunt over other treatments for refractory ascites in patients with advanced cancer.Methods The study included patients with advanced cancer with symptoms due to refractory ascites. They were randomly allocated in a 1:1 ratio to receive either peritoneovenous shunt placement (test group) or another treatment (control group). The area under the curve of the symptom improvement score was compared between the groups as the primary endpoint. The areas under the curve of the EuroQol 5-Dimension and 8-Item Short Form Health Survey were also compared between the groups, and adverse events were evaluated up to 4 weeks after enrollment or until the protocol treatment was discontinued.Results Forty patients (test group, 20; control group, 20) were enrolled between November 2009 and July 2018. The mean areas under the curve of the symptom improvement score curves were 133.2 (95% confidence interval: 98.6-167.7) and 69.9 (95% confidence interval: 34.4-105.4) in the test and control groups, respectively. The mean area under the curve was significantly larger in the test group than in the control group, and the primary endpoint was met. No significant differences were observed between the groups in the 8-Item Short Form Health Survey and EuroQol 5-Dimension scores or the frequency of adverse events.Conclusions Peritoneovenous shunt hunt significantly improved the symptoms due to refractory ascites compared with other treatments. Although it was not significantly more effective for improving the comprehensive quality of life evaluated with the 8-Item Short Form Health Survey and EuroQol 5-Dimension, peritoneovenous shunt may be considered the standard of care for patients with advanced cancer and refractory ascites.
SN - 2432-0935
ER -